BATS
vs
FTSE All Share Index

Over the past 12 months, BATS has significantly outperformed FTSE All Share Index, delivering a return of 37% compared to the FTSE All Share Index's 0% growth.
Stocks Performance
BATS vs FTSE All Share Index
Performance Gap
BATS vs FTSE All Share Index
Performance By Year
BATS vs FTSE All Share Index
British American Tobacco PLC
Glance View
British American Tobacco PLC (BAT) stands tall as a stalwart in the global tobacco industry, with a legacy intertwined with both innovation and controversy. Founded in 1902 as a joint venture between the UK’s Imperial Tobacco Company and the American Tobacco Company, BAT embarked on a trajectory that saw it become one of the world’s largest tobacco companies. Its expansive reach now spans continents, with over 200 brands in its portfolio. Managed from its London headquarters, BAT’s traditional business model revolves around the manufacture and sale of cigarettes and other tobacco products. The company generates revenue by leveraging its powerful distribution networks and established brand loyalty, with iconic names like Dunhill, Kent, and Pall Mall playing pivotal roles in its success. BAT’s profitability hinges on its ability to manage costs, scale its operations efficiently, and navigate the complex regulatory landscapes of diverse markets. In recent years, British American Tobacco has realized the need to adapt to changing consumer preferences and regulatory environments by venturing into the new category of ‘Reduced-Risk Products’ (RRPs). These include products like ‘heat-not-burn’ tobacco devices, vaping products, and oral nicotine pouches—its Vuse is a prominent brand within the e-cigarette milieu. By investing heavily in these areas, BAT aims to capture a share of the burgeoning demand for alternatives to traditional tobacco consumption, reflecting a strategic shift in its revenue streams. This pivot not only acknowledges the health risks associated with smoking but also attempts to maintain the company's market relevance amidst declining cigarette sales worldwide. BAT's story is one of adaptation and survival, striving to balance the demands of legacy products with the promise of forward-looking innovations, all while navigating the turbulent waters of public health discourse and regulatory scrutiny.
